

CURRICULUM VITAE

Michael Adriaan van Es, MD, PhD
Twijnstraat 67 bis, 3512 ZJ Utrecht
+1-858-729-3646; m.a.vanes@umcutrecht.nl
Date of birth: August 16, 1979 (Leiden, the Netherlands)
Nationality: Dutch and American
Married, 2 daughters



Education

- 2013: Post-doc in the La Spada laboratory at the University of California, San Diego (UCSD), San Diego, USA.
- 2010: PhD thesis “Unravelling the genetics of familial and sporadic ALS” (graduated from the PhD program cum laude, 22nd of April 2010).
- 2006 – present: Neurology Resident UMC Utrecht, Utrecht, The Netherlands.
Expected date of completion: 1-6-2014.
- 1997 – 2005: Medical Degree, UMC Utrecht, University Utrecht, The Netherlands.

Awards:

- Winner of the Girard de Miolet van Coehoornprize 2011 (awarded yearly by the UMC Utrecht to PhD students that completed the program cum laude).
- Winner of the Klein and Magnus award 2010 (yearly award for the best thesis from the Rudolf Magnus Institute graduate school of neuroscience).
- Winner of the Jan Meerwaldt thesis award 2010 (2-yearly award presented by the Dutch Society of Neurology for the best thesis).
- American Society of Human Genetics, Predoctoral Presentation Award Finalist (2009).
- American Society of Human Genetics, Predoctoral Presentation Award Finalist (2007).
- Winner “Prinses Beatrix Fonds” prize 2007 (national award for the best publication of the year on neuromuscular disease): van Es MA, et al. The Lancet Neurology (2007).
- Winner Rudolf Magnus Poster prize 2007: (award for the best poster at the yearly science meeting of the Rudolf Magnus Institute graduate school of neuroscience).

Grants:

- Rudolf Magnus Young Talent Fellowship 2011 (€ 200,000.- research grant to study the genetic overlap between neurodegenerative disorders (ALS, Parkinson’s disease and FTD in particular)).
- Research grant from The Thierry Latran foundation for ALS research (€ 150,000.- to identify novel risk genes for sporadic ALS by whole genome sequencing discordant monozygotic twins).
- Research grant from the Dr. Jan Meerwaldt foundation (€ 5,000.-).
- Travel grant from Girard de Miolet van Coehoorn foundation (€ 1,000.-).

Clinical trials

- Sub-investigator international ALS trial on the effect Talampanel (Teva; Pharm Ind Ltd).
- Sub-investigator national, investigator initiated placebo-controlled randomized ALS trial on the effect of sodium valproate (2005-2007).

Supervision

I have supervised one completed PhD thesis ("Complexity of familial ALS", Dr. M. van Blitterswijk, '12). I am currently supervising two PhD-students.

International meetings

- Platform presentations at the international symposium on ALS/ MND ('07,'08,'10,'12).
- Platform presentations at the American Society of Human Genetics ('07,'09).
- Platform presentations at the Dutch / Belgian neuromuscular study group ('06,'09).
- Poster presentation at the American Society of Human Genetics ('10).
- Poster presentation at the Keystone symposium; Complex genetics towards therapeutic insights (Santa Fe, USA, '08).
- Spinoza Masterclass with prof. dr. P.J. Shaw (University of Sheffield) ('07)
- Attendance at the Keystone symposium; Complex traits and disease (Big Sky, USA, '06).
- Attendance the annual meeting of the European Network for the Cure of ALS (ENCALS) ('06,'12).
- Special Colloquium & Master classes of: "The role of DNA polymorphisms in complex traits and diseases" (Molecular Medicine Post Graduate School (EMC Rotterdam, '06).

Other academic activities

- Member of the organizing committee for the Rudolf Magnus Institute Summerschool '10.
- Member of the PhD Students platform, Rudolf Magnus Institute ('08-'10).

Publications

36 publications in international, peer-reviewed journals with an average impact factor of 11.1. H-index: 18

First author (average impact factor: 16.8)

(1) van Es MA, et al. Angiogenin, a piece of the complex puzzle of neurodegeneration.

Annals of Neurology (2012) Impact factor: 11.1

(2) van Es MA, et al. Angiogenin variants in Parkinson's disease and amyotrophic lateral sclerosis. **Annals of Neurology** (2011) Impact factor: 11.1

(3) van Es MA, et al. FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. **Arch Neurol** (2010). Impact factor: 7.6

(4) van Es MA, et al. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. **JNNP** (2010). Impact factor: 4.8

(5) van Es MA, van den Berg LH. Alzheimer's disease beyond APOE. **Nat Genet** (2009). Impact factor: 35.5

(6) van Es MA, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. **Nat Genet** (2009). Impact factor: 35.5

(7) van Es MA, et al. Dpp6 is associated with susceptibility to progressive spinal muscular atrophy. **Neurology** (2009). Impact factor: 8.3

(8) van Es MA, et al. Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis. **Amyotroph Lateral Scler** (2009). Impact factor: 3.1

(9) van Es MA, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. **Neurology** (2009). Impact factor: 8.3

(10) van Es MA, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. **Nat Genet** (2008). Impact factor: 35.5

(11) van Es MA, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. **Lancet Neurol** (2007). Impact factor: 23.5

Second author (average impact factor: 6.7)

(1) van Blitterswijk M, van Es MA, et al. Mutational analysis of TARDBP in Parkinson's disease. **Neurobiol Aging** (2012) Impact factor: 6.2

(2) van Blitterswijk M, van Es MA, et al. VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. **Neurobiol Aging** (2012) Impact factor: 6.2

(3) van Blitterswijk M, van Es MA, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. **Hum Mol Genet** (2012) Impact factor: 7.6

Co-author publications (average impact factor: 8.7)

(1) Saris CG, Groen EJ, van Vught PW, van Es MA, et al. Gene expression profile of SOD1-G93A mouse spinal cord, blood and muscle. **Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration** (in press) Impact factor: 3.1

(2) van Blitterswijk M, Vlam L, van Es MA, et al. Genetic Overlap between Apparently Sporadic Motor Neuron Diseases. **PLoS One** (2012) Impact factor: 4.1

(3) Koppers M, Groen EJ, .., van Es MA, et al. Screening for rare variants in the coding region of ALS-associated genes at 9p21.2 and 19p13.3. **Neurobiol Aging** (2012) Impact factor: 6.2

(4) van Rheenen W, Diekstra FP, .., van Es MA, et al. H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. **Neurobiol Aging** (2012) Impact factor: 6.2

(5) Diekstra FP, Saris CG, .., van Es MA, et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. **PLoS One** (2012) Impact factor: 4.1

(6) van Blitterswijk M, Blokhuis A, van Es MA, et al. Rare and common paraoxonase gene variants in amyotrophic lateral sclerosis patients. **Neurobiol Aging** (2012) Impact factor: 6.2

(7) The ALSGEN Consortium. Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. **Neurobiol Aging** (2012) Impact factor: 6.2

(8) van Blitterswijk M, van Vught PW, van Es MA, et al. Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. **Neurobiol Aging** (2011) Impact factor: 6.2

(9) Shatunov A, Mok K, .., van Es MA, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. **Lancet Neurol** (2010). Impact factor: 23.5

(10) Blauw HM, Al-Chalabi A, .., van Es MA, et al. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. **Hum Mol Genet** (2010). Impact factor: 7.6

(11) Taes I, Goris A, Lemmens R, van Es MA, et al. Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse. **Neurology** (2010). Impact factor: 8.3

- (12) Bogaert E, Goris A, .., [van Es MA](#), et al. Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis. **Neurobiol Aging** (2010). Impact factor: 6.2
- (13) Kiemeny LA, Sulem P, .., [van Es MA](#), et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. **Nat Genet** (2010). Impact factor: 35.5
- (14) van der Zwaag B, .., [van Es MA](#), et al. A co-segregating microduplication of 19 chromosome 15q11.2 pinpoints two risk genes for autism spectrum disorder. **Am J Med Genet B Neuropsychiatr Genet** (2010). Impact factor: 3.7
- (15) Saris CG, Horvath S, van Vught PW, [van Es MA](#), et al. Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. **BMC Genomics** (2009). Impact factor: 2.6
- (16) Knauff EA, Franke L, [van Es MA](#), et al. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. **Hum Reprod** (2009). Impact factor: 4.5
- (17) van der Zwaag B, Franke L, [van Es MA](#), et al. Gene-network analysis identifies susceptibility genes related to glycobiochemistry in autism. **PLoS One** (2009) Impact factor: 4.1
- (18) Landers JE, Melki J,.., [van Es MA](#), et al. Reduced expression of the Kinesin- Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. **PNAS** (2009). Impact factor: 9.7
- (19) Wills AM, Cronin S,.., [van Es MA](#), et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. **Neurology** (2009). Impact factor: 8.3
- (20) Cronin S, Blauw HM, Veldink JH, [van Es MA](#), et al. Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. **Hum Mol Genet** (2008). Impact factor: 7.6
- (21) Blauw HM, Veldink JH, [van Es MA](#), et al. Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. **Lancet Neurol** (2008). Impact factor: 23.5
- (22) Sleegers K, Brouwers N, Maurer-Stroh S, [van Es MA](#), et al. Progranulin genetic variability contributes to amyotrophic lateral sclerosis. **Neurology** (2008). Impact factor: 8.3

Contributions to books

- (1) Koppers M, van Es MA, et al. Genetics of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, ISBN 979-953-307-199-1 (chapter).
- (2) van Es MA, La Spada AR. Repeat expansion disorders. Encyclopedia of Neurological Sciences (2nd Edition), in press (chapter).
- (3) van Es MA, La Spada AR. Repeat Expansion Disorders: General Concepts and Mechanisms of Disease. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (5th Edition), in press (chapter).